High-dose influenza vaccine shows increased immune response among adults 65 years of age and older
The Phase III study of almost 4,000 people 65 years of age and older compared the high-dose influenza vaccine with the standard inactivated influenza vaccine formulated for the 2006-2007 season. The key finding is that the new high-dose vaccine increased the immune responses to all three influenza strains compared with standard vaccine in the study population. An important additional observation was that the increased immune response was also observed in the potentially more vulnerable subset of study participants who had no measurable circulating protective antibodies before receiving their annual influenza vaccine.
In the randomized double-blind study conducted at 30 centers throughout the United States, 2,575 people received the high-dose influenza vaccine and 1,262 received the standard influenza vaccine. The standard influenza vaccine contained 15µg of hemagglutinin (HA) of each of three influenza strains, and the high-dose vaccine contained four times as much, 60µg HA per strain. Both vaccines contained two influenza type A strains (H1N1 and H3N2) and one influenza type B strain.
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous